Sowell Financial Services LLC Raises Stock Holdings in Pfizer Inc. $PFE

Key Points

• Sowell Financial Services LLC increased its stake in Pfizer Inc. by 10.8%, owning 197,334 shares valued at approximately $4.78 million.
• Pfizer's most recent earnings report showed an EPS of $0.78, surpassing expectations, with quarterly revenue of $14.65 billion, marking a 10.3% year-over-year increase.
• The company announced a quarterly dividend of $0.43 per share, representing a 7.2% dividend yield and a payout ratio of 91.49%.

Sowell Financial Services LLC grew its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 10.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 197,334 shares of the biopharmaceutical company's stock after purchasing an additional 19,278 shares during the quarter. Sowell Financial Services LLC's holdings in Pfizer were worth $4,783,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in PFE. Gould Capital LLC increased its holdings in Pfizer by 97.2% in the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer during the first quarter worth $27,000. North Capital Inc. acquired a new position in shares of Pfizer during the first quarter worth $28,000. Bayforest Capital Ltd acquired a new position in shares of Pfizer during the first quarter worth $28,000. Finally, Bernard Wealth Management Corp. purchased a new stake in Pfizer in the fourth quarter valued at $30,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Price Performance

Pfizer stock traded up $0.14 during midday trading on Tuesday, reaching $24.18. 26,401,369 shares of the stock traded hands, compared to its average volume of 45,276,723. The stock's fifty day moving average is $24.61 and its 200-day moving average is $24.18. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The stock has a market cap of $137.45 billion, a P/E ratio of 12.87, a PEG ratio of 0.78 and a beta of 0.55. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%.The business had revenue of $14.65 billion for the quarter, compared to the consensus estimate of $13.43 billion. During the same period in the prior year, the business posted $0.60 earnings per share. The company's quarterly revenue was up 10.3% compared to the same quarter last year. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 2nd. Investors of record on Friday, July 25th were paid a $0.43 dividend. The ex-dividend date of this dividend was Friday, July 25th. This represents a $1.72 annualized dividend and a yield of 7.1%. Pfizer's dividend payout ratio is 91.49%.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on PFE. Berenberg Bank reduced their target price on shares of Pfizer from $28.00 to $25.00 and set a "hold" rating for the company in a report on Thursday, May 29th. Citigroup increased their price target on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Morgan Stanley upped their target price on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 6th. Wall Street Zen upgraded shares of Pfizer from a "hold" rating to a "buy" rating in a research report on Saturday. Finally, Bank of America upped their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Hold" and an average price target of $28.12.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.